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ةيثارولا مدلا ضارمأ في مدلا لقن
نامع في مدلا لقن تامدخو ةيللمحا مدلا كونبل تايصوت و ةعجارم
راد انيهاس� و يمايرلا ايركز ىورأا
abstract: Sickle cell disease and homozygous β-thalassaemia are common haemoglobinopathies in Oman, with 
many implications for local healthcare services. The transfusions of such patients take place in many hospitals 
throughout the country. Indications for blood transfusions require local recommendations and guidelines to ensure 
standardised levels of care. This article summarises existing transfusion guidelines for this group of patients and 
provides recommendations for blood banks and transfusion services in Oman. This information is especially pertinent 
to medical professionals and policy-makers developing required services for the standardised transfusion support of 
these patients.
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 ديدعلا اهل يتلاو ،نامع في ةعئاس�لا ةيثارولا مدلا ض�ارما نم لثامتلما اتيب عونلا ايميس�لاثلاو ةيلجنلما ايلالخا ض�رم برتعي :ص�خللما
 .دلابلا ءاحنأا عيمج في تايفس�تس�لما نم ديدعلا في ىس�رلما ءلاؤوهل مدلا لقن تايلمع متت .ةيلحلما ةيحس�لا ةياعرلا تامدخ ىلع راثآلاا نم
 ةيهيجوتلا ئدابلما ةلاقلما هذه ض�خلت .ةياعرلا نم ةدحوم يرياعم نامس�ل ةيلمح تاداس�رإاو تايس�وت لمع مدلا لقن تاددمح بلطتت
 ةمئلام تامولعلما هذه دعتو .نامع في مدلا لقن تامدخو مدلا كونب نأاس�ب تايس�وت مدقتو ىس�رلما نم ةعومجلما هذهل ةيلالحا مدلا لقنل
.ىس�رلما ءلاؤوهل دحولما يرايعلا مدلا لقن معدل ةبولطلما تامدلخا ريوطت تاس�ايس� يعناس�و ينيبطلا ينينهملل ض�اخ لكس�ب
.نامع ؛مدلا كونب ؛مدلا لقن ؛ىمظعلا ايميس�لاثلا ؛يلجنلما مدلا رقف ض�رم ؛مدلا ضارما :ةيحاتفلما تاملكلا
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Sickle cell disease (scd) and transfusion-dependent thalassaemia, also known as thalass- aemia major (TM), are complex haemoglob-
inopathies common in Oman, with estimated carrier 
prevalence rates of 5.8% and 2.2%, respectively.1,2 
The rate of SCD is 3.7 per 1,000 live births and, in 
a community-based survey of 6,342 children, the 
prevalence rates of SCD and homozygous β-thala-
ssaemia were reported to be 0.2% and 0.07%, respect-
ively, among children under five years of age.2 This 
high prevalence can partly be explained by the 
previous endemic of Plasmodium falciparum malaria 
in the country and other parts of the Mediterranean 
region, the Middle East, Africa, India and Southwest 
Asia.3,4 An additional factor is the high prevalence 
of consanguineous marriages in Oman.5 A previous 
study on the genetic epidemiology of the sickle 
haemoglobin (HbS) mutation showed that the three 
major haplotypes—Benin (typical and atypical), Arab- 
Indian and Bantu—coexist in Oman, reflecting the 
influence of gene migration in the past from neigh-
bouring countries.6
The management of SCD and TM has a strong 
economic impact on the available national health 
services and the quality of life of the local population, 
raising the need for immediate public health action.7 A 
hospital-based study of ≤12-year-old Omani children 
with SCD reported a severe morbidity profile, defined as 
either six or more vaso-occlusive crises, hospitalisation 
for 11 days or longer, three or more blood transfusions 
or a life-threatening event, such as a haemoglobin (Hb) 
level of <5 g/dL, acute chest syndrome (ACS), acute 
splenic sequestration crises, septicaemia or stroke.8 
Another study of thalassaemic children aged 5–18 
years old found that those with higher pre-transfusion 
haemoglobin levels (i.e. ≥9 g/dL) and those who 
received red blood cell (RBC) transfusions at intervals 
of over three weeks had better overall scores according 
to the Pediatric Quality of Life Inventory™.9 Low scores 
in the school function domains were associated with 
pre-transfusion Hb levels of <9 g/dL and increased 
transfusion frequency (every ≤3 weeks).9 The former 
has been attributed to fatigue, general weakness 
and decreased mental alertness. Transfusion is also 
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associated with risks of alloimmunisation which has 
been reported among 31.6% of Omani patients with 
SCD.10 Moreover, according to unpublished data, the 
rate of alloimmunisation is 9.3% among TM patients 
in Oman.
Clinical manifestations and optimal treatment 
modalities differ for patients with SCD and TM. 
Nevertheless, RBC transfusion is an important comp-
onent in the management of both conditions. Patients 
with TM require life-long RBC transfusions for 
survival, while those with SCD require transfusions 
in specific clinical settings.11 Moreover, transfusion-
related complications, such as acute and delayed 
transfusion reactions, alloimmunisation and iron over-
load, can create additional challenges. For patients 
with SCD, the medication hydroxyurea is indicated 
in different settings, including recurrent moderate-
to-severe pain crises, a history of severe and/or 
recurrent ACS and symptomatic chronic anaemia, 
among others.12 This article summarises the existing 
literature and recommendations for transfusing 
patients with SCD and TM and discusses the potential 
impact of these recommendations on local blood 
banks and transfusion services in Oman. However, 
it is important to note that these recommendations 
serve only as a guide and should not replace clinical 
judgment in individual situations. Consultation with 
a haematologist with expertise in managing SCD and 
TM patients is advised.
Transfusion in Sickle Cell 
Disease
Transfusions in SCD patients can occur in either 
acute care settings or as part of long-term transfusion 
therapy. In some cases, transfusions are strongly 
recommended, while in others insufficient evidence 
exists to support use of this procedure. However, it is 
worth mentioning that few randomised clinical trials 
(RCTs) are available to direct clinicians as to when a 
transfusion should be considered.13–16 For patients in 
whom the indications for transfusion have limited 
evidence, the decision as to whether to transfuse 
should be based on a clinical assessment of the 
individual patient by an experienced team. 
acute settings
Acute Stroke 
Transfusions are often beneficial in the management 
of ischaemic stroke. Urgent transfusion is required 
in patients with acute neurological symptoms, with 
the aim of achieving an HbS proportion of <30%.17,18 
While this often requires an exchange transfusion, an 
initial top-up transfusion may be necessary, depending 
on the patient’s Hb level.17 It is important to avoid 
hypervolaemia during the procedure and to keep the 
patient’s post-transfusion Hb level at 10 g/dL, as a high 
haematocrit (Hct) level may worsen the neurological 
insult.17,18 No data are available at present to support 
transfusion in the acute management of haemorrhagic 
stroke or in preventing its recurrence.18 However, 
transfusion is warranted and may be a life-saving 
procedure for other SCD complications, such as acute 
haemolytic anaemia, aplastic crises, ACS and splenic 
and hepatic sequestration crises.18 
Acute Anaemia
Top-up transfusions may be necessary for SCD patients 
admitted with acute anaemia, especially symptomatic 
patients, those who show signs of imminent or 
established cardiovascular compromise or when 
accompanied by reticulocytopaenia suggestive of a 
parvovirus B19 infection.17 The threshold level for 
transfusion will depend on the patient’s baseline Hb 
level and clinical status, while the target Hb level 
should be the patient’s own steady-state Hb level.17 An 
exchange transfusion is also indicated for patients with 
exacerbated anaemia due to acute multiorgan failure 
and mesenteric syndrome.18,19
Acute Chest Syndrome
In cases of suspected ACS, it is advisable to ensure 
the availability of blood for an exchange transfusion 
ahead of time, as acute respiratory failure can develop 
rapidly and a blood transfusion can be life-saving.18 
Depending on the clinical severity of the case, either a 
simple or exchange transfusion may be warranted. In 
SCD patients with an Hb level of <9 g/dL, an early top-
up transfusion may be all that is necessary. However, 
an exchange transfusion is recommended for patients 
who have an initial Hb level of >9 g/dL, those who do 
not respond to an initial simple transfusion or in cases 
of severe or rapid ACS progression as manifested by an 
oxygen saturation level of <90% despite supplemental 
oxygen, increasing respiratory distress, progressive 
pulmonary infiltrates and/or declining Hb levels despite 
having undergone a simple transfusion.12,18,20 Although 
a target HbS proportion of 30–40% is often used, 
it is more important that the physician be guided 
by the patient’s clinical response.20 
Splenic and Hepatic Sequestration Crises
In SCD patients with splenic and hepatic sequestration 
crises, transfusions should be performed cautiously 
with small volumes following fluid resuscitation; this 
is so as to avoid hyperviscosity due to the return of 
the sequestered RBCs to the circulation system.18 For 
this reason, it is recommended that Hb levels of 8 g/dL 
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are not exceeded. A splenectomy should be considered 
in patients with recurrent episodes of two or more 
splenic sequestration crises.18
Vaso-Occlusive Crises
Transfusion is not recommended for SCD patients 
with uncomplicated painful vaso-occlusive crises, if 
no other indications for transfusion are present.12 How-
ever, it should be considered if the baseline Hb level 
has dropped substantially or there is haemodynamic 
compromise or concern of impending critical organ 
complications.18 Hydroxyurea is recommended as a 
first-line treatment for repeated painful crises, alth- 
ough it may take some time before the effect is 
perceived; transfusions can therefore be useful in the 
interim.18 
Priapism
To date, no RCTs have been conducted to evaluate the 
efficacy of transfusion in acute priapism. For priapic 
episodes, transfusions are not recommended as an 
immediate treatment modality; early interventions 
should instead include analgaesia and oral or intra-
venous hydration. However, if the episode lasts for 
longer than four hours, SCD patients may require 
transfusion in preparation for a shunt or drainage 
procedure under general anaesthesia, if the latter is 
recommended by a urologist.12 Long-term transfusion 
has been shown to reduce the incidence of priapism.21 
Patients may also benefit from an exchange transfusion 
to reduce the HbS proportion if there is no response to 
these procedures.13,18
Other Indications
There is insufficient evidence to support the benefit of 
blood transfusions in the management of SCD patients 
with leg ulcers, pulmonary hypertension, end-stage 
liver disease or progressive sickle cell retinopathy.18 
It is therefore important to consult an experienced 
haematologist for a full risk assessment and to create 
a plan for managing such patients. However, an 
exchange or simple transfusion may be useful in cases 
of severe sepsis.18,22 
long-term settings
Stroke Prevention
Long-term RBC transfusion is the mainstay of 
primary and secondary ischaemic stroke prevention 
in SCD patients.18 Multiple RCTs in paediatric SCD 
patients have assessed the benefit of transfusions 
in primary stroke prevention and in the secondary 
prevention of silent cerebral infarcts.14,21,23 Annual 
transcranial Doppler (TCD) ultrasound assessments 
are recommended for children with SCD from the 
age of two years, based on the benefits of regular 
transfusions among children with raised cerebral blood 
flow velocities (≥200 cm/second).14,17 In these chronic 
transfusion programmes, the aim is to maintain an 
HbS proportion of <30%.17,18 These transfusions should 
be continued throughout child-hood as a significant 
number revert to high TCD velocities or develop overt 
stroke after the transfusions are discontinued.18,23 
In children with SCD and high cerebral blood 
flow velocities without new magnetic resonance 
imaging-related changes, severe magnetic resonance 
angiography (MRA)-defined cerebral vasculopathy 
or prior transient ischaemic attacks, hydroxyurea 
should be considered after initiating a regular trans- 
fusion programme for primary stroke prevention for 
a minimum of one year. Data from the Transcranial 
Doppler with Transfusions Changing to Hydroxyurea 
(TWiTCH) trial indicated that hydroxyurea was 
efficacious and not inferior to blood transfusions 
for primary stroke prevention in children.15 However, 
transfusions should be continued in patients with severe 
MRA-defined cerebral vasculopathy and are effective 
in reducing recurrence among SCD children with silent 
cerebral infarcts.21 No studies have been conducted to 
assess the efficacy of regular transfusions for primary 
stroke prevention in adult SCD patients or in patients 
undergoing long-term transfusion programmes since 
childhood. Moreover, TCD has not been validated in 
adults; therefore, its utility in assessing stroke risk in 
this patient group is unknown.18
According to the results of the Stroke with 
Transfusions Changing to Hydroxyurea (SWiTCH) RCT, 
monthly transfusions and iron chelation were more 
effective than hydroxyurea in preventing ischaemic 
stroke recurrence among SCD children with a history 
of stroke, with seven stroke events occurring in the 
hydroxyurea group compared to no events in the 
transfusion group.16 Long-term transfusions to 
maintain an HbS proportion of < 30% rather than 
hydroxyurea are therefore recommended for sec-
ondary stroke prevention. Transfusions may be needed 
indefinitely, although they do not completely abolish 
the risk of recurrence; as such, risk factors should be 
reviewed regularly with patients and/or their parents 
or guardians.18 As with primary stroke prevention, 
there is no evidence of the benefit of transfusions 
for secondary stroke prevention among adult 
SCD patients. However, based on paediatric trials, 
long-term regular transfusions are recommended 
to maintain an HbS proportion of <30%.18 Other 
indications for long-term transfusions include patients 
with contraindications for hydroxyurea and those 
with progressive organ failure, recurrent ACS or vaso-
occlusive crises not prevented by hydroxyurea.17,18 
The specific management approach for these patients 
should be decided on an individual case-by-case basis. 
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Preoperative Indications
There is currently no consensus as to which SCD 
patients require preoperative transfusions.17 The Trans- 
fusion Alternatives Preoperatively in Sickle Cell 
Disease trial provides the most compelling evidence 
to support the use of preoperative transfusions.13 In 
this trial, patients undergoing low- or medium-risk 
surgeries were randomised to receive either a pre-
operative transfusion—a simple transfusion if Hb 
levels were <9 g/dL or an exchange transfusion if 
Hb levels were ≥9 g/dL—or no transfusion at all. 
Patients in the non-transfused group had significantly 
higher rates of complications and serious adverse 
events, particularly ACS, as compared to the trans-
fused patients.13 While the optimal method of trans-
fusion is debatable, currently available evidence 
indicates that simple transfusions are not inferior to 
exchange transfusions.13,24 
Vichinsky et al. reported that conservative 
transfusions aiming to raise Hb levels to 10 g/dL were 
as effective in preventing postoperative complications 
as aggressive exchange transfusions intending to 
reduce HbS proportions to <30%.24 Both simple (in 
patients with Hb levels of <9 g/dL) and exchange (in 
patients with Hb levels of ≥9 g/dL) transfusions for an 
Hb target level of 10 g/dL are recommended for SCD 
patients undergoing low- (e.g. adenectomies and dental 
procedures) or medium-risk (e.g. tonsillectomies and 
abdominal or orthopaedic surgeries) procedures. How- 
ever, exchange transfusions are recommended for 
patients undergoing high-risk surgeries such as cardio-
vascular operations.18 For patients requiring emergency 
surgeries, as long as they are not unduly delayed, 
simple transfusions can be given preoperatively with 
the aim of achieving an Hb level of 10 g/dL.18
Pregnancy
Prophylactic transfusions should be considered in 
pregnant patients with previous or current medical, 
obstetric or fetal SCD-related complications, patients 
who were previously taking hydroxyurea for severe 
SCD and those with multiple-gestation pregnancies.18 
However, routine prophylactic transfusions are not 
recommended during pregnancy as there is insufficient 
evidence to substantiate their role.25,26 Women receiv-
ing long-term transfusions for other indications 
should continue regular transfusions throughout their 
pregnancy.27 
Transfusions in Homozygous 
β-Thalassaemia
Homozygous β-thalassaemia is a genetic disorder 
that affects the synthesis of β-globin chains, leading 
to chronic anaemia and ineffective erythropoiesis 
due to imbalanced globin synthesis. It can be broadly 
categorised clinically as either TM or thalassemia 
intermedia (TI). In TM, Hb production is markedly 
reduced and regular transfusions from infancy are 
critical to keep the patient alive.28 In TI, patients can 
survive without lifelong regular transfusions; however, 
certain indications may necessitate transfusion.29 
Transfusion therapy in β-thalassaemia is effective in 
supplying normal erythrocytes and suppressing in-
effective erythropoiesis to a large extent.30 
thalassaemia major
Regular blood transfusions every 3–4 weeks are 
the standard therapy for TM.11 Once an infant is 
diagnosed with homozygous β-thalassaemia, close 
monitoring from the age of three months is required 
to detect clinical signs indicative of the need to initiate 
regular transfusions, with Hb levels checked on at 
least a monthly basis. The current guidelines of the 
Thalassemia International Federation for initiating 
regular transfusions include severe anaemia (<7 g/dL 
on two occasions one to two weeks apart) or Hb levels of 
>7 g/dL accompanied by inappropriate fatigue, poor 
feeding, developmental delay or regression or symp-
toms of heart failure, after excluding contributing 
causes such as infections.11 Other reasons to initiate 
transfusion regardless of Hb levels include a failure to 
thrive, progressive splenomegaly, fractures, clinically-
significant extramedullary haematopoiesis and/or the 
appearance of thalassaemic facies.11,31 
It is important to reassess infants after the initial 
transfusion; if Hb levels fall again, it is reasonable to 
assume long-term dependency necessitating a regular 
transfusion programme.31,32 The decision to begin 
regular transfusions usually occurs within the first two 
years of life.11 Where possible, this decision should 
not be delayed beyond three years as the risk of 
alloimmunisation increases with age, as does the 
difficulty of finding suitable RBC units.31 Regular 
transfusion programmes in children should aim for 
trough pre-transfusion Hb levels of 9–10.5 g/dL.31,33 
Occasionally, TM patients with cardiac disease, extra-
medullary haematopoiesis and/or inadequate bone 
marrow suppression benefit from higher transfusion 
Hb thresholds of 11–12 g/dL, although there is limited 
evidence to support this approach.31 
Once initiated, transfusions are usually given 
every 2–4 weeks.31 With older patients, a transfusion 
every two weeks may be necessary to maintain a 
trough Hb level of 9–10.5 g/dL.31,34 A splenectomy is 
sometimes indicated for patients with hypersplenism 
and for those with high transfusion requirements.35 
A transfusion record should be maintained and 
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include the volume or weight of administered units, 
the Hb/Hct level of the units, the patient’s weight, the 
occurrence of any transfusion reactions and if any RBC 
antibodies have formed.11,36 Transfusion requirements 
are likely to increase in pregnant patients.27 In patients 
undergoing elective surgery, a preoperative assessment 
should include the transfusion history and pre- and 
perioperative transfusions should be planned to 
ensure an Hb level of 10–12 g/dL. Post-transfusion Hb 
levels should not be higher than 14–15 g/dL to avoid 
the risk of hyperviscosity and stroke.11 
thalassaemia intermedia 
Patients with TI have mild or moderate haemolytic 
anaemia and can maintain an Hb level of >7 g/dL 
without regular transfusion support.32 These patients 
may have worsening anaemia, particularly upon 
exposure to physiological stress or other triggers. 
The decision to transfuse in TI cases depends on 
several factors beyond Hb level.37 Children should 
be monitored carefully for evidence of thalassaemic 
features resulting from ineffective erythropoiesis, 
bone marrow expansion, a reduction in growth or 
progressive splenomegaly. If there is evidence of any of 
the above, the child should receive regular transfusions 
until they have reached their full adult height and the 
bones are fused.31 Older children, adolescents and adults 
should continue to be monitored regularly for any 
indications that may arise. Some adolescents require 
transfusions because of poor growth, delayed/absent 
puberty or complications due to bone expansion.38 
During adulthood, periodic transfusions may be 
indicated during acute episodes of anaemia, especially 
for pregnant patients, those suffering from infections 
or prior to surgery.38–40 Transfusions should be consid- 
ered in the management of certain conditions, for 
primary prevention in high-risk populations and 
for secondary prevention in some settings. Indic-
ations include the development of thrombotic or 
cerebrovascular disease, pulmonary hypertension with 
or without secondary heart failure, extramedullary 
haematopoietic pseudotumours and leg ulcers.38 
Although transfusions have been shown to protect 
against these complications, increased risks due to 
iron overload, endocrinopathies and alloimmunisation 
should be taken into account when deciding the optimal 
time to transfuse such patients.41 During pregnancy, 
transfusions should be considered in mothers with TI 
and worsening anaemia or if there is evidence of fetal 
growth retardation; the aim should be to maintain 
a pre-transfusion Hb level of >10 g/dL.42 Once the 
transfusion programme is initiated, patients should be 
closely monitored and therapy should be individually 
tailored to meet their needs.38 Some patients with 
TI may need to continue regular transfusions. 
Such a decision should be made in consultation 
with a specialist with experience in managing TI 
patients.31,43
Alloimmunisation
A major complication of transfusion in patients with 
SCD and homozygous β-thalassaemia is the risk of 
alloimmunisation. Risk factors for alloimmunisation 
are complex and involve at least three contributing 
elements: (1) RBC antigenic differences between the 
blood donor and the recipient, (2) the recipient’s 
immune status and (3) the immune-modulatory effects 
of the transfused RBCs on the recipient.44 Increased 
systemic inflammation and dysregulation of the 
immune system may also be responsible for allo-
immunisation in SCD patients.45,46 Several studies 
have shown a rising risk of alloimmunisation among 
SCD patients corresponding with an increase in the 
number of transfusions received.47–49 
Red cell alloimmunisation presents a challenge 
to blood banks, especially when trying to find 
compatible blood for affected patients. Following 
alloimmunisation, serious complications may occur 
such as life-threatening delayed haemolytic transfusion 
reactions and transfusion delays due to difficulties in 
finding compatible units. Alloimmunisation further 
triggers autoantibody formation in transfused 
SCD and thalassaemic patients, with a cumulative 
incidence of 6–10%.44,50–52 Although the development 
of these autoantibodies is less frequent compared to 
the development of alloantibodies, they can cause 
clinically significant haemolysis and difficulty in 
obtaining compatible RBC units.53 The most common 
antibodies observed in patients with SCD and homo-
zygous β-thalassaemia are those against the rhesus 
(Rh), particularly the C and E antigens, and the Kell (K) 
systems.54 Other antibodies that tend to develop are 
against the Kidd, Duffy, Lewis and MNS systems.54
Reported alloimmunisation rates in SCD vary. In 
patients with SCD receiving only ABO- and D-matched 
RBCs, the rate of alloimmunisation ranges from 18% 
to as high as 76%.47,48,52,55–59 The exact rate is dependent 
on many factors, including the extent of RBC antigen 
matching, the degree of homogeneity between the 
recipients’ and donors’ ethnic backgrounds and the 
frequency of transfusion. The Rh and anti-K antibodies 
comprise over two-thirds of the RBC antibodies 
encountered.60 The risk of alloimmunisation has been 
shown to be reduced to 5–11% with additional limited 
antigen phenotype matching for C, E and K antigens 
and to 0–7% with extended phenotype-matched 
RBCs.45,59,61,62 Therefore, compatible RBCs which have 
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been fully cross-matched for all Rh and K antigens is 
the minimum recommended standard of transfusion 
care for patients with SCD.17,18,60,63 Extended RBC 
phenotypes should ideally be performed in the first 
year of life, before the start of a regular transfusion 
programme.31,36 If the patient has been recently 
transfused, DNA-based methods can be used to 
determine the predicted phenotype.64
If alloantibodies are identified, the RBCs used 
for the transfusion should be negative for the corr-
esponding antigen. Extended RBC phenotype-match- 
ing for Duffy, Kidd and MNS antigens has also been 
recommended to reduce the risk of alloimmunisation 
against these antigens.65 However, this can be problem- 
atic, as such additional testing increases costs and is 
dependent upon the availability of the necessary 
inventory, laboratory personnel and resources. That 
being said, establishing a limited inventory of O group 
RBCs negative for the C, c, E, e and K antigens in blood 
banks may be cost-effective, as well as decreasing the 
need to process blood on an urgent basis and shortening 
the time to transfusion.66 Molecular methods are 
particularly useful in patients with recent transfusions 
and no baseline phenotype as well as patients with 
autoantibodies and complex alloimmunisation.67 Comp- 
arative studies show that alloimmunisation and delayed 
haemolytic transfusion reactions are less frequent in 
automated RBC exchange transfusions compared to 
chronic simple transfusions, despite increased blood 
exposure.68–70 However, this finding may be due to the 
fact that some patients receive RBCs with a higher 
degree of phenotype-matching during automated 
exchange transfusions.71 These types of transfusions 
also have the advantage of limiting iron overload in 
these patients, a variable which has been associated 
with increased morbidity.72 
According to various reports, the rate of allo-
immunisation among TM patients ranges from 5.2–37%, 
although it appears to be lower among more homo-
geneous populations.44,60,73–78 This variation has been 
linked to the extent of the homogeneity between the 
donor-recipient populations, divergent testing methods 
and differences in the patient population of each 
study.75,79 Other factors include the use of non-leuko- 
reduced RBC units and differences in providing antigen-
matched blood.67 The lower rates of alloimmunisation 
in TM compared to SCD are probably due to the 
fact that transfusions for thalassaemic patients begin 
at a relatively younger age and are continued on a 
regular basis. No consensus exists on the provision 
of extended antigen-matching in TM patients due to 
limited data on the impact of RBC-matching policies 
on alloimmunisation rates in such patients. Research 
has been published regarding the impact on the rate 
of alloimmunisation of providing limited C, E and K 
antigen-matched RBCs in comparison to ABO and D 
antigen phenotype-matched RBCs.44,80 Nevertheless, 
this approach has been questioned considering the low 
rate of alloimmunisation in this population.79 However, 
clinical standards recommend antigen-matching for 
all Rh and K antigens in order to minimise the risk 
of alloimmunisation in patients with homozygous 
β-thalassaemia.11,31,34,36
Alloimmunisation is more common in TI than 
in TM.80,81 Risk factors for alloimmunisation in TI 
patients include a history of splenectomy, pregnancy 
and patients who have never been transfused or 
have been only minimally transfused before.31,39,43,82 
Previous research has demonstrated the value of 
providing extended RBC antigen-matching for the Rh 
(C, c, E and e), K (K, Kpa and Kpb), Kidd (Jka and Jkb), 
Duffy (Fya and Fyb), S and s antigens in reducing 
alloimmunisation rates among patients with TI.82 As 
RBC alloimmunisation is common in TI, phenotype-
matched units are recommended.31,39,43,82 
The association between leukoreduction and 
RBC alloimmunisation has not been well established.75 
It has been hypothesised that leukoreduction lowers 
the frequency of RBC alloimmunisation.83 Hussein 
et al. reported a higher rate of RBC alloimmunisation 
among patients receiving non-leukoreduced RBCs 
compared to those always receiving leukoreduced 
RBCs.84 Due to its benefit in reducing the risk of 
febrile reactions and cytomegalovirus transmission, 
leukoreduction has become an increasingly common 
procedure and standard of care in many centres caring 
for patients with SCD and thalassaemia.67,85
Other Transfusion 
Requirements
For both SCD and TM patients, the RBC units to be 
transfused should be fresh (between <7–14 days old) 
and, in the case of SCD patients, negative for sickle 
cells.17,31 If possible, a hepatitis B immunisation course 
should be completed prior to the first transfusion. 
Serological testing for hepatitis A, B and C and HIV 
should also be performed to obtain baseline values. It 
is recommended that all patients who lack serological 
immunity to the hepatitis B virus begin a vaccination 
programme and show evidence of immunity before 
the start of the transfusion.17,34,36 Following the start 
of the transfusion programme, patients should be 
regularly screened for hepatitis and HIV.
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Recommendations in Oman
In Oman, patients with haemoglobinopathies are 
managed and treated at various regional hospitals 
throughout the country. Implementation of the afore-
mentioned recommendations will necessitate that all 
blood banks have the required testing facilities for 
extended RBC phenotyping, antibody screening and 
identification. In addition, healthcare institutions will 
need to have access to pre-storage leukoreduced RBC 
units, maintain an accurate and comprehensive patient 
record database and develop facilities for automated 
RBC exchange transfusions. Accordingly, the develop-
ment of an interconnected blood bank system through- 
out Oman is recommended, from which information 
on blood groups, baseline extended phenotypes and 
existing allo- and autoantibodies can be shared 
between different blood banks. Until these measures 
are implemented, patients should be provided with 
an up-to-date transfusion card detailing their blood 
group, baseline extended phenotype, existing anti-
bodies and date of antibody formation, if any, as well 
as baseline Hb levels for patients with SCD. Such 
a measure would aid in ensuring that these patients 
receive adequate management and standard levels of 
care when presenting to different hospitals in Oman.
Moreover, an active donor recruitment prog-
ramme is required to ensure the availability of blood 
for Omani patients with SCD or thalassaemia. A 
limited antigen-negative RBC inventory should be 
established in major hospitals treating patients with 
these haemoglobinopathies. A centralised database of 
phenotyped blood donors accessible to all blood banks 
is also needed to allow the identification of suitable 
RBC units for transfusing potentially problematic 
alloimmunised patients. In addition, a frozen blood 
facility of rare RBC phenotypes for use in difficult 
situations should be established, along with molecular 
testing methods in major centres to facilitate the 
immediate management of complex alloimmunised 
cases. Table 1 summarises recommendations for blood 
banks and transfusion services in Oman. 




• Extended RBC phenotyping for Rh (C, c, E and e), K (K, Kpa and Kpb), Kidd (Jka and Jkb), Duffy 
(Fya and Fyb), S and s antigens should be performed before the start of a regular transfusion prog-
ramme, ideally within the first year of life. If this is not available, then extended RBC phenotyping 
can be performed on a pre-transfusion sample after a minimum of three months following an RBC 
transfusion. 
• If the patient has been recently transfused, DNA-based methods can be used to determine the 
predicted phenotype. 
• RBC antigen matching for Rh and K antigens is recommended as a standard of care in non-allo-
immunised SCD cases due to the increased risk of alloimmunisation to these antigens. 
• RBC antigen matching for Rh and K antigens is recommended in TM patients to minimise the risk 
of alloimmunisation.  
• Extended RBC antigen matching is recommended in TI patients since they have an increased risk of 
alloimmunisation compared to TM patients. 
• If alloantibodies are identified in SCD or TM patients, extended RBC phenotype matching is 
recommended. The selected units should be serologically cross-match compatible with the patient’s 
serum and tested to ensure negativity to the corresponding antigens. 
• If extended phenotype matching is unavailable, transfused RBCs in alloimmunised patients should 
be at the very least serologically cross-matched and tested to ensure negativity to the corresponding 
antigen.
Screening • Antibody screening should be performed before each transfusion.
Serology and immunity • Serological testing for hepatitis A, B and C and HIV should be performed at baseline and every six 
months thereafter. 
• All patients who do not have serological immunity to the hepatitis B virus should start a vaccination 
programme and show evidence of immunity before the start of the transfusion, if possible.
Monitoring • Due to the risk of iron overload and related cardiac, hepatic and endocrinological complications, 
patients should be closely monitored and chelation therapy should be initiated when indicated.
Blood bank records • Every patient should have a complete and up-to-date blood bank record of antigen typing, antibodies 
and transfusion reactions. This information should be used to assess the blood type and phenotype 
needed prior to each transfusion.
Other • RBC units for both SCD and TM patients should be fresh (<7–14 days old). 
• RBCs for SCD patients should be sickle cell-negative.  
• Pre-storage leukoreduced RBC components should be used as much as possible for patients with 
SCD and homozygous β-thalassaemia. 
• An automated RBC exchange transfusion facility is recommended in centres that care for larger 
numbers of SCD patients as this transfusion method is a more efficient way to perform exchange 
transfusions and reduces the degree of iron overload.
RBC = red blood cell; Rh = rhesus; K = Kell; SCD = sickle cell disease, TM = thalassaemia major; TI = thalassaemia intermedia.
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Conclusion
Major haemoglobinopathies such as SCD and TM have 
specialised transfusion requirements. This article 
provides various recommendations to enhance exist- 
ing blood banks and transfusion services in Oman, 
based on a review of the current literature regarding the 
transfusion practices for such patients. The provision 
of such services will require additional funding, 
administrative support, expertise, training and human 
resources, as well as the development of an active 
donor recruitment programme and interconnected 
blood bank system within the country.
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